|
Mitochondrial Myopathies
|
0.010 |
Biomarker
|
group |
BEFREE |
Cloning of the human mitochondrial 51 kDa subunit (NDUFV1) reveals a 100% antisense homology of its 3'UTR with the 5'UTR of the gamma-interferon inducible protein (IP-30) precursor: is this a link between mitochondrial myopathy and inflammation?
|
9571201 |
1998 |
|
melanoma
|
0.050 |
Biomarker
|
disease |
LHGDN |
The absence of GILT in melanomas altered antigen processing and the hierarchy of immunodominant epitope presentation.
|
12021307 |
2002 |
|
melanoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
In contrast with professional APCs such as B cells, class II-positive human melanomas expressed relatively little to no GILT protein or mRNA.
|
15240658 |
2004 |
|
Leukemia, Myelocytic, Acute
|
0.300 |
Biomarker
|
disease |
CTD_human |
Discovery of epigenetically silenced genes in acute myeloid leukemias.
|
17330099 |
2007 |
|
Acute Myeloid Leukemia, M1
|
0.300 |
Biomarker
|
disease |
CTD_human |
Discovery of epigenetically silenced genes in acute myeloid leukemias.
|
17330099 |
2007 |
|
Acute Myeloid Leukemia (AML-M2)
|
0.300 |
Biomarker
|
disease |
CTD_human |
Discovery of epigenetically silenced genes in acute myeloid leukemias.
|
17330099 |
2007 |
|
Dermatitis, Allergic Contact
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression time course in the human skin during elicitation of allergic contact dermatitis.
|
17597826 |
2007 |
|
melanoma
|
0.050 |
Biomarker
|
disease |
LHGDN |
These data suggest that GILT-expressing melanoma cells could prove to be very promising for direct antigen presentation and CD4+ T cell recognition, and may have direct implications for the design of cancer vaccines.
|
18343923 |
2008 |
|
Neuromyelitis Optica
|
0.010 |
Biomarker
|
disease |
BEFREE |
Pathologically, CD68(+) macrophages and microglia expressed intense immunoreactivities for IFI30 and CD163 in NMO lesions, consisting of inflammatory demyelination, axonal loss, necrosis, cavity formation, and vascular fibrosis.
|
18410276 |
2008 |
|
Neuromyelitis Optica
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
Neuromyelitis optica/Devic's disease: gene expression profiling of brain lesions.
|
18410276 |
2008 |
|
Experimental Organism Basal Cell Carcinoma
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Additionally, we found increased expression of interferon (IFN)-regulated genes (including IFI27, IFI30, Mx1, IRF1 and CXCL9) in SCC, and to a lower extent in BCC.
|
18770863 |
2008 |
|
Carcinoma, Basal Cell
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Additionally, we found increased expression of interferon (IFN)-regulated genes (including IFI27, IFI30, Mx1, IRF1 and CXCL9) in SCC, and to a lower extent in BCC.
|
18770863 |
2008 |
|
Cardiovascular Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Given the importance of low-grade inflammation in obesity-related metabolic complications, we hypothesized that variants in the IFI30 gene are associated with cardiovascular disease (CVD) risk factors.
|
21701784 |
2012 |
|
Hyperglycemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A polymorphism of the interferon-gamma-inducible protein 30 gene is associated with hyperglycemia in severely obese individuals.
|
21701784 |
2012 |
|
Metabolic Syndrome X
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A previous expression profiling of visceral adipose tissue (VAT) revealed that the immune response gene interferon-gamma-inducible protein 30 (IFI30) gene was 1.72-fold more highly expressed in non-diabetic severely obese men with the metabolic syndrome as compared to those without.
|
21701784 |
2012 |
|
Obesity
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The IFI30 rs11554159 polymorphism could partially explain the inter-individual variability observed in the inflammatory profile associated with obesity.
|
22178353 |
2012 |
|
Hemophilia B
|
0.010 |
Biomarker
|
disease |
BEFREE |
The results show that administering 500 μL of NMP via IV or IP 30 min in advance enables surgical procedures to be safely performed on HB mice, and that IV administration is more desirable than IP if the procedure requires opening of the abdominal wall.
|
23855819 |
2013 |
|
Multiple Sclerosis
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.
|
24076602 |
2013 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
The role of gamma-interferon-inducible lysosomal thiol reductase (GILT) in tumor immunosurveillance has recently been studied in several malignant diseases, but its role in breast cancer remains to be elucidated.
|
25333930 |
2014 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, absence of GILT was positively correlated with adverse characteristics of breast cancers, such as histological type, tumor size, lymph nodes status, and pTNM stage (P<0.05).
|
25333930 |
2014 |
|
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To further determine the role of GILT in breast cancer, we examined GILT expression in breast cancers as well as noncancerous breast tissues by immunohistochemistry and real-time PCR, and assessed its association with clinicopathologic characteristics and patient outcome.
|
25333930 |
2014 |
|
Tumor Immunity
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
These findings indicate that GILT may act as a tumor suppressor in breast cancer, in line with its previously suggested role in anti-tumor immunity.
|
25333930 |
2014 |
|
melanoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
GILT staining in antigen-presenting cells (APCs) was detected in 100% of primary and metastatic melanomas versus 31% of nevi, and it was typically intense.
|
26930048 |
2016 |
|
Nevi and Melanomas
|
0.010 |
AlteredExpression
|
group |
BEFREE |
We evaluated GILT and MHC class II expression in human primary and metastatic melanomas and nevi using immunohistochemical analysis.
|
26930048 |
2016 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
FTO (OR = 1.71; CI<sub>95 %</sub> = 1.14-2.57; p = 0.008) and APOB (OR = 0.31; CI<sub>95 %</sub> = 0.14-0.72; p = 0.004) result is statistically associated to high blood pressure and FTO (OR = 2.0; CI<sub>95 %</sub> = 1.3-3.1; p = 0.001), GNB3 (OR = 2.69; CI<sub>95 %</sub> = 1.0-7.2; p = 0.04), IFI30 (OR = 2.0; CI<sub>95 %</sub> = 1.16-3.6; p = 0.01), and MC4R (OR = 1.81; CI<sub>95 %</sub> = 1.13-2.9; p = 0.01) to type 2 diabetes (T2D).
|
28035522 |
2017 |